Abbott Laboratories stock faces strategic test after Nutrition spin-off plan

Abbott Laboratories stock remained in focus on Wednesday, November 4, after the company outlined a plan to separate its Nutrition business into an independent publicly traded company. Abbott announced the transaction on October 21, with completion targeted for the end of 2027, subject to regulatory approvals and other conditions, according to Abbott.

Abbott Laboratories stock traded at 98.60 euros on Lang & Schwarz at 13:08 CET on Wednesday, November 4, 2026. The quote keeps the portfolio reshaping plan in focus while investors assess the future earnings mix of the remaining healthcare group.

Two businesses with different priorities

The planned separation would place brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure in the new Nutrition company. Abbott expects that business to have annual sales of 8.5 billion US dollars, about 16,000 employees and 14 manufacturing sites.

Abbott intends to distribute shares in the new company to existing shareholders in a transaction designed to qualify as tax-free for US federal income tax purposes. Once completed, shareholders would own shares in both Abbott and the independent Nutrition company. Abbott has not yet announced the final distribution ratio.

Daniel Salvadori, currently Abbott's executive vice president and group president for Established Pharmaceuticals and Nutritional Products, is slated to become chief executive of the new company. The Nutrition business will remain part of Abbott during the separation process.

Focus shifts to execution

Following the separation, Abbott expects to retain approximately 42 billion US dollars in sales and concentrate on medical devices, biowearables, diagnostics and established medicines. Chief Executive Robert Ford said the two companies would have different investment requirements, growth profiles and innovation cycles, allowing capital allocation to align more closely with each business model.

The company said the separation will not affect its 2026 guidance or the 2027 outlook it plans to provide in January. Abbott also expects to incur one-time transaction charges before completion, although it has not yet quantified them. Investors will therefore watch the registration process, regulatory approvals, the allocation of liabilities and the financial profile disclosed for the future Nutrition company.

Abbott Laboratories stock is part of a healthcare portfolio exposed to medical technology, diagnostics and pharmaceutical demand. The transaction could make the remaining business easier to assess, but the benefits depend on execution, the treatment of separation costs and the ability of both companies to sustain growth after the split.

Broader sentiment for US healthcare shares can be followed through the S&P 500.

Further updates will center on the planned regulatory filings, the separation timetable and Abbott's 2027 guidance. More news and analyses on Abbott Laboratories stock will track these milestones.

Real-time quote of Abbott Laboratories stock is available for investors monitoring the share.